Table 1.

Failed phase 3 trials on anti-amyloid therapy in AD since 2016

Year	Drug	Mechanism of action	Participants	Main reasons for failure	Remarks
2016	Solanezumab	Monoclonal antibody	Mild AD	Lack of efficacy
	Solanezumab	Monoclonal antibody	Prodromal AD	Strategic
	Verubecestat	BACE inhibitor	Mild to moderate AD	Lack of efficacy
2018	Verubecestat	BACE inhibitor	Prodromal AD	Lack of efficacy	Worsens cognition
	Atabecestat	BACE inhibitor	Preclinical AD	Toxicity	Worsens cognition
	Lanabecestat	BACE inhibitor	Early AD	Lack of efficacy	Worsens cognition
	Lanabecestat	BACE inhibitor	Mild AD	Lack of efficacy	Worsens cognition
2019	Aducanumab	Monoclonal antibody	Early AD	Lack of efficacy
	CNP520	BACE inhibitor	Preclinical AD	Lack of efficacy	Worsens cognition